Renalytix Plc (RNLX) Return on Equity ROE from the first quarter 2025 to first quarter 2024 and annually, average high and low, overall ranking from Sep 30 2024 to Sep 30 2023 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Renalytix Plc  (RNLX)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare

Renalytix Plc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Renalytix Plc in the first quarter 2025?
Due to the lack of equity, it was not possible to calculate Renalytix Plc's return on equity (ROE) in its first quarter 2025

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2024)
I. Quarter		 (Jun 30 2024)
IV. Quarter		 (Mar 31 2024)
III. Quarter		 (Dec 31 2023)
II. Quarter		 (Sep 30 2023)
I. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -28 -33 -72 -76 -113
Return On Equity (TTM) - - - -1955.61 % -1394.33 %
RNLX's Total Ranking # # # # #
Equity (TTM) in Millions -11 -8 -11 -8 -1
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to RNLX Management Effectiveness >> RNLX's 5 Years Annual ROE >> Compare RNLX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





RNLX Annual Return On Equity (Jun 30 2024)
2024		 (Jun 30 2023)
2023		 (Jun 30 2022)
2022		 (Jun 30 2021)
2021		 (Jun 30 2020)
2020
Total Equity in Millions -8 7 31 71 16
Y / Y Equity Change - -77.24 % -57.17 % 349.1 % -
Net Income in Millions -33 -46 -45 -34 -10
Y / Y Net Income Change - - - - -
Return On Equity - -654.61 % -147.93 % -47.74 % -61.87 %

Back to RNLX Management Effectiveness >> RNLX's 5 Years Annual ROE >> Compare RNLX ROE to its Competitors




More Return On Equity Ratios
Medical Laboratories Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
RNLX's' Return on Equity at Yahoo Finance
RNLX's Roe Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for RNLX's Competitors
Subscribers only: Roe for Renalytix Plc's Suppliers
Subscribers only: Return On Equity for RNLX's Customers




Companies with similar Return On Equity at Sep 30 2024, within Healthcare Sector ROE
Hca Healthcare Inc   613.42 %
Gridai Technologies Corp  555.42 %
Alaunos Therapeutics Inc   424.57 %
Longduoduo Co Ltd  214.51 %
Keenova Therapeutics Plc  172.76 %
Halozyme Therapeutics Inc   156.40 %
Lifecore Biomedical Inc   125.51 %
Davita Inc   118.75 %
Viskase Holdings inc   108.91 %
3m Company  95.37 %
Earth Science Tech Inc   86.24 %
Tenet Healthcare Corp  85.17 %
Roivant Sciences Ltd   76.18 %
Dariohealth Corp   72.16 %
Agios Pharmaceuticals Inc   70.20 %
Amgen Inc   68.49 %
Nrc Health  67.40 %
Tg Therapeutics Inc   66.04 %
Abbvie Inc   65.52 %
Eli Lilly And Company  64.74 %
Mimedx Group Inc   63.54 %

Date modified: 2026-08-31T16:10:08+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.